Efficacy of a heterologous vaccine and adjuvant in ferrets challenged with influenza virus H5N1

Influenza and other Respiratory Viruses

Volumn 6, Issue 5, 2012, Pages 328-340

  Vela, Eric M ^a   Buccellato, Mathew A ^a   Tordoff, Kevin ^a   Stark, Greg ^a   Bigger, John E ^a  

^a BATTELLE MEMORIAL INSTITUTE   (United States)

Author keywords

H5N1; Heterologous vaccine; Highly pathogenic avian influenza

Indexed keywords

ALUMINUM HYDROXIDE ADJUVANT CLAG 1073; AVIAN INFLUENZA VACCINE; CLAG 1323 VACCINE; CLAG 1324 VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOPSY; AVIAN INFLUENZA VIRUS; CONTROLLED STUDY; DRUG EFFICACY; FERRET; INFLUENZA VIRUS A H5N1; INFORMATION PROCESSING; LETHAL DOSE; NONHUMAN; PRIORITY JOURNAL; SEROLOGY; SURVIVAL; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM HYDROXIDE; ANIMALS; DISEASE MODELS, ANIMAL; FERRETS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; ORTHOMYXOVIRIDAE INFECTIONS; SURVIVAL ANALYSIS; VACCINATION;

EID: 84865302565     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/j.1750-2659.2011.00321.x     Document Type: Article

References (21)

1. Crosby A. Epidemic and Peace. Westport, CT: Greenwood Press, 1976.
2. Webster RG, Bean W, Gorman O, Chambers T, Kawaoka Y. Evolution an decology of influenza A viurses. Microbiol Rev 1992; 56:152-179.
3. Taubenberger J, Reid A, Lourens R, Wang R, Jin G, Fanning T. Characterization of the 1918 influenza viurs polymerase genes. Nature 2005; 437:889-893.
4. Bragstad K, Jorgensen P, Handberg K, Mellergaard S, Corbet S, Fomsgaard A. New avian influenza A virus subtype combination H5N7 identified in Danish mallard ducks. Virus Res 2005; 109:181-190.
5. Cumming G, Caron A, Abolnik C et al. The ecology of influenza A viruses in wild birds in Southern Africa. EcoHealth 2011; 8:4-13.
6. Williams R, Xiao X, Peterson A. Continent-wide association of H5N1 outbreaks in wild and domestic birds in Europe. Geospat Health 2011; 5:247-253.
7. World Health Organization. Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO, 2008.
8. Nicholson KG, Colegate AE, Podda A et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001; 357:1937-1943.
9. Treanor JJ, Wilkinson BE, Masseoud F et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 2001; 19:1732-1737.
10. Reuman PD, Keely S, Schiff GM. Assessment of signs of influenza illness in the ferret model. J Virol Methods 2004; 24:27-34.
11. Zitzow LA, Rowe T, Morken T, Shieh WJ, Zaki S, Katz JM. Pathogenesis of Avian Influenza A (H5N1) Viruses in Ferrets. J Virol 2002; 76:4420-4429.
12. Peiris M, de Jong M, Guan Y. Avian influenza virus (H5N1): a threat to human health. Clinical Microbiology Reviews 2007; 20:243-267.
13. Areechokchai D, Jiraphongsa C, Laosiritaworn Y, Hanshaoworakul W, O'Reilly M. Investigation of avian influenza (H5N1) outbreak in humans - Thailand, 2004. MMWR Morb Mortal Wkly Rep 2006; 28:3-6.
14. Dinh P, Long H, Tien N et al. Risk factors for human infection with avian influenza A H5N1, Vietnam, 2004. Emerg Infect Dis 2006; 12:1841-1847.
15. Writing Committee of the Second World Health Organization Consultation of Clinical Aspects of Human Infeciton with Avian Influenza A (H5N1) Virus. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 2008; 358:261-273.
16. Hehme N, Engelmann H, Kuenzel W, Neumeier E, Saenger R. Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. Virus Res 2004; 103:163-171.
17. Harada Y, Ninomiya-Mori A, Takahashi Y et al. Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice. Vaccine 2011; 29:8330-8337.
18. Ninomiya A, Imai M, Tashiro M, Odagiri T. Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model. Vaccine 2007; 25:3554-3560.
19. Gustin KM, Maines TR, Belser JA et al. Comparative immunogenicity and cross-clade protective efficacy of mammalian cell-grown inactivated and live attenuated H5N1 reassortant vaccines in ferrets. J Infect Dis 2011; 204:1491-1499.
20. Maines TR, Lu XH, Erb SM et al. Avian influenza (H5N1) viruses isolated from humans in Asia in 2004 exhibit increased virulence in mammals. J Virol 2005; 79:11788-11800.
21. Layton R, Gigliotti A, Armijo P et al. Enhanced immunogenicity, mortality protection, and reduced viral brain invasion by alum adjuvant with an H5N1 split-virion vaccine in the ferret. PLoS ONE 2011; 6:e20641.